The estimated Net Worth of Venture Fund X, L.P.Atlas V... is at least 4.15 百万$ dollars as of 19 July 2019. Venture V owns over 810,811 units of Magenta Therapeutics Inc stock worth over 3,897,102$ and over the last 6 years Venture sold MGTA stock worth over 254,416$.
Venture has made over 2 trades of the Magenta Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Venture bought 810,811 units of MGTA stock worth 15,000,004$ on 19 July 2019.
The largest trade Venture's ever made was buying 810,811 units of Magenta Therapeutics Inc stock on 19 July 2019 worth over 15,000,004$. On average, Venture trades about 206,264 units every 30 days since 2018. As of 19 July 2019 Venture still owns at least 5,567,289 units of Magenta Therapeutics Inc stock.
You can see the complete history of Venture V stock trades at the bottom of the page.
Venture's mailing address filed with the SEC is 400 Technology Square, 400 Technology Square, Cambridge, MA 02139, USA.
Over the last 6 years, insiders at Magenta Therapeutics Inc have traded over 6,775,591$ worth of Magenta Therapeutics Inc stock and bought 1,257,000 units worth 10,105,000$ . The most active insiders traders include Bruce Booth、Rock Ventures Iv, L.P.Third...、Jeffrey W. Albers. On average, Magenta Therapeutics Inc executives and independent directors trade stock every 46 days with the average trade being worth of 99,614$. The most recent stock trade was executed by Rock Ventures Iv, L.P.Third... on 7 February 2023, trading 3,700,000 units of MGTA stock currently worth 3,071,000$.
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.
Magenta Therapeutics Inc executives and other stock owners filed with the SEC include: